Bristol-Myers Squibb Co (BMY) Stock Analysis
Verdict: HOLD
Robust FCF yield of 8.9% and 4.58% dividend support valuation, but revenue patent cliffs in 2028-2029 limit upside potential.
Investment score: 63/100
Analysis as of
Is Bristol-Myers Squibb Co stock worth reviewing? The TradeMates thesis
The TradeMates model rates Bristol-Myers Squibb as a HOLD. Low earnings valuation (13.88x P/E) and dependable free cash flow ($12.85B in 2025) protect the 4.58% dividend yield, but impending 2028 patent cliffs cap upside momentum.
7-factor investment score
- Valuation: 75/100 (weight 20%)
- Financial Health: 55/100 (weight 15%)
- Technical Momentum: 70/100 (weight 15%)
- Earnings Quality: 85/100 (weight 15%)
- Insider Sentiment: 35/100 (weight 10%)
- Analyst Consensus: 50/100 (weight 10%)
- Risk-Adjusted Return: 55/100 (weight 15%)
Bristol-Myers Squibb Co opportunities and risks
What speaks for BMY
- Strong Free Cash Flow and Dividend Protection
What speaks against BMY
- Impending 2028 Revenue Cliff from Loss of Exclusivity (LoE)
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| BMY | 13.9x | 2.6x | 9.7x | 70.2% | 18.9% | 8.9% |
| LLY | 43.7x | 15.4x | 29.5x | 83.4% | 33.5% | 1.6% |
| JNJ | 40.6x | 6.5x | 21.8x | 68.8% | 16.2% | 3.2% |
| MRK | 116.9x | 5.5x | 29.5x | 75.4% | 4.8% | 4.4% |
| PFE | 40.2x | 2.7x | 17.5x | 71.3% | 6.8% | 6.3% |
| RPRX | 26.4x | 11.2x | 21.3x | 89.4% | 32.1% | 10.5% |
| Peer median | 40.6x | 6.5x | 21.8x | 75.4% | 16.2% | 4.4% |
Frequently asked questions about Bristol-Myers Squibb Co (BMY)
Is BMY stock a good investment?
The TradeMates model rates Bristol-Myers Squibb Co as HOLD with an investment score of 63/100. The TradeMates model rates Bristol-Myers Squibb as a HOLD. Low earnings valuation (13.88x P/E) and dependable free cash flow ($12.85B in 2025) protect the 4.58% dividend yield, but impending 2028 patent cliffs cap upside momentum. This is algorithmic model output, not personal investment advice.
Is BMY stock a buy?
The TradeMates model verdict for BMY is HOLD with an investment score of 63/100. Treat this as a model signal to review, not a personal buy recommendation.